



Vascularized organoid-on-chip platforms: Expanding the bioengineering frontiers with microfluidics

Rocktotpal Konwarh^{1,*}

¹ Baba Kinaram Research Foundation, 769/1-A, Brahmsthan Sahadatpura, Mau, Uttar Pradesh, 275101, India;

Article History

Submitted:

Accepted:

Published:

Abstract

Organoids-on-a-chip (OoC) technology is a pivotal advancement in biomedical research, engineered to meticulously replicate the intricate physiological functions of organs within controlled *in vitro* microenvironments. A critical component for elevating the biological fidelity and physiological relevance of these advanced platforms is the integration of a functional vascular system, vital for nutrient and oxygen delivery, waste removal, and intricate cell-cell communication. In this context, microfluidic technology has proven to be an exceptionally powerful tool. Its unparalleled precision in controlling fluid dynamics and engineering microscale architectures facilitates the creation of perfusable and functional 3D microvasculature within a wide array of OoC systems. Gearing off with a comprehensive note on the approaches to harness microfluidics for such platforms, the content in this article is streamlined towards understanding the advantages and key challenges of the technology. Furthermore, the nuances and the progress in the realm are reflected through a discussion on recent exemplary studies, illustrating the diverse biomedical applications of microfluidic-driven vascularized OoC (vOoC) systems.

Keywords

Organoid-on-a-chip; Vascularization; Microfluidics; Disease Modeling; 3D Microvasculature; Perfusability; Tissue engineering

Introduction

Recent explorations into smart biomaterials with robust biophysicochemical attributes, including unique nanoscale features, have significantly advanced the field of bioengineering [1, 2]. Concurrently, progress in various rapid prototyping approaches [3] and the research thrust on biofabrication of physiologically relevant biomimetic structures using 3D bioprinting, electrospinning [4], and microfluidics [5-7] has provided a tremendous fillip to this realm. Amongst others, organoids as innovative 3D,

self-organizing cell cultures of different lineages have received considerable impetus for modeling diverse tissues and organs [8]. They significantly advance understanding of developmental and disease biology, offer patient-specific insights into various health threats, and hold promising potential for regenerative cell therapies. However, the absence of a functional vascular network can be a major block in exploiting their potential to replicate *in vivo* physiology and support clinical translation. Vascularization is indispensable for ferrying essential nutrients and oxygen as well as recruitment of immune cells within en-

engineered tissues, thereby, regulating tissue survival, regeneration, and homeostasis [9]. Without adequate blood supply, necrosis sets in. By the same token, vascularization facilitates the elimination of metabolic waste products.

The human circulatory system is a complex network of blood vessels, ranging from large arteries and veins to tiny capillaries, each with vital roles in various bodily functions. Blood vessel formation primarily involves *vasculogenesis*, the formation of new blood vessels from progenitor cells, and *angiogenesis*, the growth of new vessels from existing ones. Angiogenesis involves the coordinated activity of specialized tip cells that lead the sprouting process and stalk cells that follow [9]. This intricate process is essential for various biological functions, including growth and development. Furthermore, it is well established that neovascularization profoundly affects wound healing, impacting the quality of new tissue formation [10]. While biomaterial-based approaches can be employed to enhance angiogenesis or vasculogenesis in a spatially, temporally, or spatiotemporally controlled manner, cell-based strategies enable the targeting of neovascularization by modulating the responses of angiogenic cells at the wound site. A key concept in vascular network formation is the establishment of a hierarchical organization, where vessels of different sizes and functions (arterioles, capillaries, and venules) are spatially and temporally coordinated. This hierarchy is essential for efficient blood flow and tissue perfusion. Endothelial cell (EC) heterogeneity, differential expression of angiogenic factors, and dynamic cell–cell interactions contribute to vessel hierarchy formation [11]. Additionally, mechanical forces like blood flow patterns and tissue stiffness influence the organization and remodeling of vessel networks.

The creation of vascularized organoids employs several advanced bioengineering strategies [12]. A widely used approach involves (a) co-culturing ECs with supportive cells like pericytes and fibroblasts, which stimulates the self-organization of vessel-like structures within the organoid. Alternatively, (b) integrating lineage-specific organoids with pre-formed vascular organoids enhances vascular incorporation and functional integration. The technique of (c) organoid co-differentiation, guides stem cells to simultaneously develop into both organ-specific and vascular cell types, promoting synchronized tissue development. (d) Embedding organoids into microfluidic devices (organoid-on-a-chip, OoC) allows dynamic perfusion and improved physiological fidelity [13], while (e) 3D bioprinting enables the precise spatial placement of cells and materials to fabricate organoids with predefined vascular networks. Each method offers distinct advantages: co-culture and co-differentiation are biologically intuitive and mimic natural developmental processes, vascular organoid integration accelerates network formation, OoC provides controlled perfusion and

real-time analysis, and bioprinting offers architectural precision. However, limitations persist—self-assembly lacks control over vessel geometry, vascular organoid fusion may face integration challenges, co-differentiation requires finely tuned protocols, organ-on-chip systems demand technical expertise and may face material constraints (e.g., absorption of small molecules by polydimethylsiloxane (PDMS) [14]), and bioprinting may affect cell viability and depends on evolving bioinks. Together, these methods reflect a balance between biological realism and engineering control, with each suited to specific applications in disease modeling, tissue engineering, or drug testing.

On a specific note, vascularized OoC (vOoC) models have opened new research avenues, enabling the study of drug pharmacokinetics and pharmacodynamics as well as the investigation of vascular-related diseases, all within a more physiologically relevant *in vitro* environment [9, 15]. These are complemented by advancements in detection, analysis, and organoid imaging, particularly with artificial intelligence (AI), thereby enhancing OoC functionality and drug screening [7]. Although, the number of publications and patents on OoC technology is constantly increasing, challenges remain, including multi-organ integration, and whole-body modeling (an endeavor towards human-on-a-chip model). Nevertheless, the vOoC platforms enable researchers to observe dynamic vascular processes, such as angiogenesis and cell interactions, in real time. Similarly, vessel-on-a-chip/vasculature-on-a-chip (VoC) models may be harnessed to study oxygen and nutrient transport as well as mimic various functional tissue/vascular barriers (e.g., blood brain barrier, alveolar-capillary interface, renal vascular tubular unit, human placenta) [16]. With this backdrop, let us now specifically delve into the microfluidics assisted vOoC platforms in the following section.

Advantages and Approaches of Microfluidics Assisted vOoC Platforms

vOoCs- The advantages

A comparative assessment of different contemporary biological research models by Chaudhari et al. (2025) [17] revealed distinct pros and cons. While animal models provide dynamic complex cell-cell interactions and intrinsic vasculature, they introduce ethical considerations and lack precise control or high-throughput screening. Traditional 2D cultures are severely limited across various parameters. Organoids improve ethical considerations and screening but typically lack intrinsic vasculature, controlled microenvironments, and dynamic mechanical cues. In contrast, microfluidic 2D cultures and especially OoC models present significant advantages. As mentioned previously, these advanced platforms facilitate *in vitro* vascularization, offer precise microenvironmental

control, ensure continuous nutrient supply, and enable the emulation of mechanical cues and real-time data sensing, greatly enhancing physiological relevance and research throughput. Thus, microfluidic chips have become a highly effective platform for *in vitro* microvasculature modeling, owing to their numerous advantageous features [18, 19]:

- (a) Microfluidic systems offer high spatial and temporal regulation of the cellular microenvironment, enabling fine manipulation of cell behavior and tissue development.
- (b) They enable the formation of perfusable microvessels ranging from 20–50 μm in diameter by modulating interstitial flow within the extracellular matrix (ECM), thereby closely mimicking the dimensions and functional characteristics of native human microvasculature.
- (c) Through emulation of mechanical cues and creation of controlled gradients of biochemical cues such as growth factors and signaling molecules, which are essential for cell differentiation and tissue patterning.
- (d) They allow real-time data sensing, precise control of flow rates and shear stresses, facilitating physiologically relevant fluid flow patterns across the engineered tissue.
- (e) Continuous perfusion ensures a constant supply of oxygen and nutrients while efficiently removing metabolic byproducts, thereby promoting sustained cell health and function.
- (f) Microfluidic models can replicate the hierarchical architecture of vascular networks, offering a physiologically relevant model of vascular complexity. They can create 3D vascular architecture, including the circular cross-section of blood vessels and luminal/apical-to-albuminal/basal polarity, both of which are crucial for directed secretion of proteins involved in lumenogenesis.
- (g) These systems can be tailored to study a wide range of physiological and pathological aspects of vascular biology, making them valuable tools for translational research and drug testing.
- (h) Techniques, such as injection molding and laser cutting can facilitate the mass production of these chips (with relatively simple architecture), making them suitable for high-throughput screening of vascularized organoids.

Strategies towards developing vOoCs

Several microfluidic techniques for engineering vOoCs exist [17]. Droplet microfluidics enables high-throughput assays by isolating organoids in controlled microenvironments, while perfusion microfluidics overcomes diffusion limits by mimicking blood flow. Integration with hanging-drop systems supports 3D organoid formation and vascularization. Advanced co-culture platforms promote angiogenesis and tissue viability. Furthermore, automated microfluidic systems enable large-scale organoid production with real-time monitoring, offering scalable, precise platforms for regenerative medicine and

personalized therapeutic development. A detailed discussion of these is beyond the scope of this article.

Nevertheless, microfluidics approach for vascularization can be broadly categorized into the wall-trapping method and the microencapsulation method [15] while biomimetic vasculature is also being created using innovative techniques, including viscous fingering and the application of leaf venation patterns [13]. Varma and Fathi's categorization of various *in vitro* vascularization strategies in OoC platforms [13] illustrates the inherent trade-off between simplicity/researcher control and physiological fidelity.

The most straightforward method, EC-lined channels with fluid flow connected to culture chamber, offers ease of implementation and precise control over perfusion, making it suitable for basic flow studies or medium exchange. Based on the material used, the fabrication-approach for microchannels can be classified as [18]: (a) Hydrogel-based: Microneedle-based method (creates single channels); Micropatterned, planar hydrogel method (creates single-layer channel network); Dissolvable material-based sacrificial micro-molding method (creates multi-layer channel network).

(b) PDMS-based: Requires coating with extracellular matrix (ECM) proteins like laminin, fibronectin, and collagen IV to enhance cell adhesion.

However, the fundamental limitation of this approach is the inability to recapitulate the complex, hierarchical branching akin to native vasculature, thus restricting its utility for comprehensive studies of vascular development or pathology.

Conversely, methods relying on EC-based self-assembly to form microvasculature under static conditions represent a significant step towards biological realism by mimicking *in vivo* vessel formation. While this offers a greater faithful morphological representation of microvasculature, the critical absence of fluid flow effects is a major physiological shortcoming. Interstitial fluid flow and hemodynamic forces, such as shear stress, are crucial regulators of EC behavior, orientation, morphogenesis, and vessel maturation *in vivo*. Therefore, static self-assembly models may fall short in addressing questions where mechanotransduction or flow-mediated remodeling is paramount.

The artificial biomimetic network creation attempts to bridge this gap by allowing researchers to design and control complex network geometries, potentially offering a more similar *in vivo*-like structure than simple channels. However, since the network is not formed *de novo* through biological self-organization, there lies a question about the extent to which its functional and molecular characteristics truly mirror those of native vasculature. Furthermore, the potential for interactions between cells and synthetic scaffold materials, if not sacrificial, may introduce an additional layer of complexity and potential confounding factors.

Ultimately, self-assembled microvasculature under flow conditions emerges as the most physiologically relevant approach. By combining the natural process of biological self-assembly with the essential physiological cue of fluid flow, this method holds the greatest promise for faithfully recapitulating *in vivo* vascular networks. Such high fidelity is crucial for developing predictive models of vascular diseases, assessing drug efficacy, or understanding complex angiogenesis.

A critical component of vOoC systems is the incorporation of hydrogel-based channels, which serve both as a scaffold for vessel formation and as a conduit for nutrient and waste exchange. This structural and functional integration is essential for sustaining tissue viability and modeling vascular phenomena under controlled experimental conditions [19]. However, the significant technical challenges associated with its successful implementation, particularly in achieving stable and controlled perfusion across multiple interconnected compartments in multi-organ chips, currently limit its widespread adoption. The choice of vascularization method must, therefore, be strategically aligned with the specific research question, balancing the need for biological complexity with practical feasibility and throughput.

Exemplary endeavors and applications

Microfluidics technology has been employed for various biomedical studies, *e.g.*, heart-on-a-chip platform for *in vitro* cardiomyocyte monitoring (crucial for cardiac drug screening and disease modeling applications) [20] and sensors-integrated gut-on-a-chip model, simulating the intestinal barrier for *in situ* monitoring of Hg(II) transport and absorption [21] merit mention. On a specific note, microfluidics-assisted vOoC platforms have been harnessed to provide a comprehensive insight into the angiogenesis and vasculogenesis processes. To cite for evidence, research using microfluidic chips indicated that pericytes, via a mechanism involving interleukin-6, are more effective in promoting vascularization compared to stromal cells [22]. Similarly, Zhang et al. (2022) demonstrated that interstitial flow (IF) significantly enhances the formation, density, and perfusability of self-organized microvascular networks (MVNs) in a microfluidic system, by upregulating matrix metalloproteinase-2 (MMP-2). Validated with a brain MVN model, the strategy was projected apt to boost diverse organotypic MVN development for bioengineering applications [23]. Shakeri et al. (2023) [24] have critically assessed the design features, fabrication-materials, biofunctional interfaces, and key progress of various OoC models for modeling different vascular diseases (atherosclerosis, thrombosis, vascular

dysfunctions, inflammation, malformation, pulmonary arterial hypertension, ischemia, etc.).

In a parallel vein, tumor-on-a-chip (ToC) models have received a considerable research thrust. For example, Lansche et al. (2025)'s patient-derived, vascularized ToC (vToC) model revealed cancer cells and cancer-associated fibroblasts (CAFs) induce endothelial anergy by downregulating VCAM-1 leukocyte adhesion protein and immunomodulatory chemokines, offering a clinically relevant platform for tumor-CAF-immune-endothelium interaction studies [25]. Similarly, use of organotypic pancreatic ductal adenocarcinoma (PDAC)-on-a-chip model to understand tumor vascular invasion and tumor-blood vessel interactions revealed activin-ALK7 signaling mediated endothelial ablation [26]. Angiogenesis chips can also be used to recreate tumor microenvironment and study tumor growth, investigate the role of angiogenesis in cancer, and screen drugs. In the realm of cosmetology, skin-on-a-chip models are being developed to replace animal testing (*e.g.*, Jusoh et al. (2019)'s microfluidic model utilized the angiogenic response, stimulated by irritated keratinocytes to predict skin irritation by chemical irritants [27]).

The progress in vascularized microfluidic models of different structures (including heart, liver, kidney, skin, endometrium, *etc.*) as well as studies on neurovascular unit-on-a-chip and vascularized tumor-on-a-chip platforms have been the subjects of multiple recent reviews [7, 9, 13, 16, 17]. As an exemplary piece of evidence, Mozneb et al. (2024) [28] presented a novel microfluidic OoC that integrates human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) (representing heart muscle, myocardium) and hiPSC-ECs (representing vasculature) in a dynamic environment with active fluid flow and rhythmic biomechanical stretch. This advanced model augmented cellular maturity (functional and genetic), mimicked physiological conditions (endothelial barrier permeability), and enabled the investigation of multi-lineage cardiotoxicity (induced by VEGFR2/PDGFR-inhibiting tyrosine kinase inhibitors (VPTKIs) (chemotherapeutic agent)). By improving the prediction of cardiotoxicity, this technology holds prospects to accelerate drug development and potentially reduce the risk of therapy-induced adverse cardiovascular events in cancer patients. By the same token, readers may go through Arslan et al. (2024)'s protocol for developing a microfluidic organ-on-chip platform that enables the generation of human induced pluripotent stem cell (hiPSC)-derived cardiac microtissues with perfusable blood vessels [29].

At this juncture, for the illustration of the nuances and the growth in the realm, let me cite a few more exemplary studies in the subsequent section.




Figure 1

[1] [A] Generation of pre-vascularized pancreatic islet spheroids {involving the use of EndoC-βH5 (Human primary β cells), FMA73 (Primary human fibroblasts), and RFP-labelled HUVEC} for on-chip culture within a HUVEC endothelial bed and under flow conditions. [B] Schematic

diagram of glucose stimulation and collect of secretions performed on-chip. Comparison of the [C] insulin secretions and [D] stimulation index of the pancreatic islet spheroids between the various culture conditions. Each point on the graph represents the stimulation index of one pancreatic islet obtained from the measure of low and high glucose stimulation. Scale bar, 100 μm (a). Data represents mean $\pm$ s.d. Statistical significance was attributed to values of $P < 0.05$ as determined by unpaired t test (two-tailed). $*P < 0.05$ ($P = 0.017$ (static w/o vasc.), $P = 0.029$ (static with vasc.), $P = 0.037$ (flow without vasc.)), $***P < 0.001$. (Reproduced from Quintard et al. (2024) [14] under the provisions of <http://creativecommons.org/licenses/by-nc-nd/4.0/>. Copyright © 2024, The Author(s)).

[2] [A, B] Schematic representation of the microfluidic chip on a CAM. Prototypes A and B are shown in lateral and top view with dimensions. The mouse embryonic kidney is schematically vascularized by capillaries originating from the chick embryo chorioallantoic membrane (CAM). Created with <https://BioRender.com>. [C] Detection of the blood vessels in mouse embryonic kidneys in different variants of the experiment. Positive control: intact mouse embryonic kidney dissected from E12.5 embryo (A–C). Negative control: mouse embryonic kidney dissected from E12.5 embryo, cultivated 5 days in vitro (D–F). *In vivo* experiment. Mouse embryonic kidney E12.5 was vascularized on a chicken embryo CAM for 4–5 days (G–I). *In vivo* experiment after continuation *in vitro*. Mouse embryonic kidney E12.5 was vascularized on the chicken CAM for 4–5 days, and then cultivated 5 days under *in vitro* conditions (J–L). CD31 was used as an endothelial marker (red) and Hoechst as a nuclear marker (blue). Scale bars = 50 μm . (Reproduced from Oliveira et al. (2024) [31] under the provisions of Creative Commons Attribution 3.0 (Unported) Licence. Copyright © The Royal Society of Chemistry 2024)

[3] ECs penetrate hepatic microtissues forming lumenized, perfusable microvasculature. [A] Maximum intensity projection of hepatocyte spheroid co-cultured with microvessels for 7 days and stained against albumin (green) and CD31 (red). Scale bar: 200 μm . [B] Maximum intensity projection of hepatocyte organoids co-cultured with microvessels for 21 days and stained against albumin (green) and CD31 (red). Scale bar: 200 μm . [C] Single-plane confocal images of hepatocyte spheroid co-cultured with microvessels for 7 days and stained against albumin (green) and CD31 (red). Lumenized spaces are observable in the vessels connecting the main tubes to the hepatocyte spheroid (i, white arrow) and in close proximity of hepatocytes (ii, white arrow). Scale bar: 200 μm (i) and 50 μm (ii). [D] Cryo-sections of spheroids co-cultured for 1 (i), 4 (ii), and 7 (iii) days on microvascular beds stained against albumin (green), CD31 (red), and nuclei (blue). White arrow indicates penetration of CD31 + ECs inside the hepatocyte spheroid. Scale bar: 200 μm . [E] EM images of sections of hepatocyte organoids co-cultured with microvessels for 7 days indicating ECs with distinct lumen (i) and vascular-hepatic contact point (ii) with intracellular pinocytotic vesicles (iii, white arrow). Scale bar: 10 μm . [F] Schematic depiction of flow through the chip to assess perfusability of vascularized liver cultures using 150-KDa FITC-labeled dextran. [G] Over-time fluorescence microscopy images of 150-KDa FITC-labeled dextran perfusing a hepatocyte spheroid co-cultured for 7 days with microvessels. Dotted ellipse indicates FITC-labeled dextran emerging from the spheroid and flowing in the lateral perfusion channel (Reproduced from Bonanini et al. (2022) [34] under the provisions of <http://creativecommons.org/licenses/by/4.0/>. Copyright © 2022, The Author(s))

[4] Representation of the vascularized human liver tumor model based on a microfluidic platform, designed to test both drug and cell-based therapies (Reproduced from Vasudevan et al. (2025) [35] under the provisions of <https://creativecommons.org/licenses/by/4.0/>. Copyright © 2025 The Authors. Published by Elsevier Ltd.)

[A] In a topical investigation, a microfluidic chip-based *in vitro* model was developed to recapitulate the early stages of *human endochondral ossification*, with an emphasis on vascular interactions [30]. Building on prior *in vivo* models using human embryonic stem cell (hESC)-derived sclerotome implanted in immunodeficient mice, the researchers developed an OoC system to simulate vascular invasion. Fibrin gel proved more effective than collagen-I gel in aligning mCherry-labeled human umbilical vein ECs (HUVECs), facilitating the formation of perfusable, vascular-like networks. Incorporating hESC-derived sclerotome and enhanced green fluorescent protein (EGFP)-expressing HUVECs produced SH (Sclerotome + HUVECs) organoids, which exhibited augmented maintenance and organization of vascular structures. Interestingly, the authors reported the migration and partial integration of the EGFP-expressing HUVECs with pre-established mCherry-HUVEC networks. Immunohistochemistry revealed spatially distinct expression of SRY-box transcription factor 9 (SOX9) in mesenchymal condensates and type I collagen in perichondrial-like regions, further validating the model's physiological relevance. The platform may be applied to understand vascular dynamics in human endochondral ossification, modeling genetic bone conditions and drug discovery in skeletal biology. However, the limitations, including incomplete skeletal cell maturation hindering cartilage vascular invasion, unachieved intra-organoid vascular perfusion, and chip

system constraints on long-term SH organoid culture cannot be overlooked.

[B] Quintard et al. (2024) developed a novel cyclic olefin copolymer (COC)-based microfluidic platform for generating vOoC, specifically designed to overcome challenges like manual operation and PDMS material incompatibilities [14]. The system ensured stable, two-week-long perfusion at 1 $\mu\text{L}/\text{min}$ via a syringe pump, allowing continuous multi-channel monitoring. A key innovation involved passive loading of organoids and hydrogels into hydrodynamic traps, minimizing shear stress and facilitating interconnected, multi-organoid array formation. The platform reproducibly generated perfusable endothelial networks, recapitulating *in vivo* vascular patterning and achieving physiologically relevant blood flow velocities ($v = 100\text{--}7500 \mu\text{m}/\text{s}$) and shear rates ($\dot{\gamma} = 25\text{--}2000 \text{ s}^{-1}$). Crucially, successful anastomosis between a HUVEC endothelial bed and human blood vessel organoid capillaries demonstrated intravascular perfusion. This study further attested flow and vascularization-mediated enhancement of *pancreatic islet spheroid* function: a high glucose challenge upscaled insulin secretion, but a significantly higher stimulation index was observed only with both fluid flow and an integrated HUVEC vascular bed, indicating a synergistic effect critical for an enhanced functional β -cell niche (Figure 1 [1]). Current challenges include significant cell loss during hydrogel encapsula-

tion and difficulties in precisely adjusting gel layer thickness, impacting scalability and efficiency.

[C] Likewise, a novel microfluidic chip was introduced by Oliveira et al. (2024) to achieve sequential *in vivo* organoid vascularization and subsequent successful transition to *in vitro* culture, critical for sophisticated tissue modeling [31]. The study evaluated two PDMS chip prototypes using the chicken chorioallantoic membrane (CAM) model. Both designs utilized a standard three-channel architecture, with the central channel, loaded with mouse embryonic kidneys (MEKs) and hydrogel for vascularization, flanked by lateral channels for medium perfusion (**Figure 1 [2] [A, B]**). Prototype A allowed initial chicken-derived vessel infiltration into the hydrogel, but its design hindered successful chip detachment, rendering the vascularized tissue unsuitable for further *in vitro* analysis. This limitation was overcome by Prototype B, which incorporated a refined membrane with 30 μm pores. This modification facilitated robust vessel ingrowth while preserving hydrogel and MEK structural integrity during chip detachment from CAM, enabling reliable *ex ovo* vascularization and seamless transfer to *in vitro* culture for longitudinal studies. The addition of vascular endothelial growth factor (VEGF) within the hydrogel, in combination with endogenous VEGF production by embryonic kidneys, effectively directed angiogenic sprouting from the CAM into the chip. Vascularization occurred within 3–5 days, with functional blood flow confirmed. The critical transition step to *in vitro* culture required meticulous removal of residual CAM tissue, avoiding medium leakage. Comparative analysis of vascular development under different conditions (**Figure 1 [2] [C]**) demonstrated the efficacy of the novel system. While MEKs cultured exclusively *in vitro* without CAM transplantation showed a significant reduction in their vascular network, samples vascularized on the CAM successfully integrated chicken-derived capillaries with pre-existing mouse vessels, restoring circulation and promoting continued vascular development. Crucially, samples vascularized on the CAM using Prototype B and subsequently transferred to *in vitro* conditions maintained intact mouse-derived blood vessels forming a robust vascular network, with minimal degradation of the kidney tissue. This work established a highly functional platform for *initiating in vivo organoid vascularization and effectively sustaining it in vitro*, thereby advancing dynamic tissue modeling.

[D] Cerebral neovascularization is intrinsically regulated by metabolic demands and profoundly influences neurodevelopmental processes such as neuronal plasticity, gliogenesis, and neurogenesis [32]. Reciprocally, molecular factors from neurons and surrounding cells dictate EC behavior and angiogenic potential. Given the intricate and incompletely understood nature of cerebral vascularization, alongside challenges in its *in vitro* recapitulation,

Shaji et al. (2024) aimed to delineate the molecular mechanisms governing neurovascular crosstalk crucial for establishing functional *in vitro* vascularized cerebral organoid (CO) systems [32]. Their microfluidic CO-vascular bed (CO-VB) co-culture system, combined with transcriptomic profiling of the CO's outermost cell layer on a preformed vascular bed, revealed highly orchestrated regulation of numerous pro-angiogenic factors and their downstream effectors. The platform sustained CO lineage integrity and pre-formed VB integrity for up to 10 days, though the angiogenic response within the CO attenuated after day 7. Transcriptome analyses indicated a temporal regulation of angiogenic potential, with early activation (day 31) and subsequent suppression (day 35) of key pro-angiogenic genes, particularly VEGFA, and catenin beta-1 (CTNNB1). Furthermore, Cysteine-Rich Angiogenic Inducer 61 (CYR61) and Hepatoma-Derived Growth Factor (HDGF) were found to augment vascular sprout formation in the CO, suggesting their functional involvement in central nervous system (CNS) angiogenesis. Although, the study provided crucial insights for advancing *in vitro* brain vascularization strategies, the use of non-brain specific HUVECs and human lung fibroblasts (hLFs) seemed to potentially limit the fidelity of the neurovascular mimicry *vis-à-vis* the specialized structures of the brain vasculature—the blood brain barrier (BBB) with pericytes and other stromal cells. Future research could be directed towards incorporation of brain-specific microvascular ECs or induced pluripotent stem cell (iPSC)-derived ECs, adopting perfusion-based culture systems, and applying spatial omics or single-cell sequencing strategies to better characterize the dynamic vascularization landscape in COs.

[E] Casademont-Roca et al. (2025) [33] recently introduced the first spongy *urethra-on-a-chip* model, based on F300R microfluidic device and a rocking system. A significant achievement was the successful formation of microvessel-like structures by co-culturing HUVECs with pericytes within 3.5% gelatin-transglutaminase hydrogels. Crucially, even a low fluid shear stress of 0.049 dyne/cm² was sufficient to promote a confluent urethral epithelial monolayer with organized tight junctions under dynamic conditions. These vasculogenic hydrogels also demonstrated the capacity to support the infiltration and proliferation of chicken ECs in CAM assay. While promising, limitations include the use of mixed species cells, a fluid shear stress significantly lower than physiological levels, and challenges in hydrogel cross-linking. Despite these, evinced by the successful recapitulation of both the epithelial and vascular compartments under dynamic flow, the platform is envisaged to offer a valuable tool for investigating urethral stricture disease mechanisms and preclinical drug screening.

[F] In an effort to achieve *in vitro* tissue grafting, Bonanini et al. (2022) designed an open-top microfluidic

platform, facilitating the direct introduction of target tissue via manual or robotic pipetting [34]. The system's 384-well microtiter plate integrated 64 microfluidic chips, each supporting angiogenesis and microvascular network formation between two main lateral vessels. They demonstrated the *vascularization and subsequent perfusion of liver tissue constructs* (Figure 1 [3]). A key validation was achieved by mimicking *veno-occlusive disease* (VOD) through azathioprine exposure, which induced a measurable loss of network perfusability and localized microvascular cell death, providing a functional readout for disease modeling. Critical comparison of liver tissue constructs revealed distinct outcomes: both liver spheroids and pre-vascularized spheroids achieved anastomoses, but pre-vascularized spheroids displayed a two-fold higher success rate in establishing perfusable cultures, underscoring the crucial advantage of endogenous endothelium for functional network formation. In contrast, liver organoids did not reliably induce anastomosis or perfusability. The authors critically hypothesized that this limitation stemmed from the growth factor-rich organoid culture medium and potential hindrance from the collagen-Matrigel interface, impeding vascular elongation and interconnection. The platform's broad applicability extends beyond liver tissue, envisioned for vascularizing other organoids (e.g., brain, kidney) and tumor tissues, offering a more efficient alternative to time-consuming and variable patient-derived xenograft models. Future research directions could involve incorporating specialized cells like Liver Sinusoidal ECs (LSECs) and other non-parenchymal cells (e.g., stellate and Kupffer cells) to enhance physiological fidelity for complex disease modeling.

[G] Vasudevan et al. (2025) introduced the innovative OrganiX™ microfluidic platform for enhanced *in vitro* vascularized tumor modeling and therapeutic discovery (Figure 1 [4]) [35]. The 24-well system with removable inserts supports high-throughput analyses and diverse downstream assays. Its significant capacity to accommodate tumors of diameter up to 2 mm enables the recapitulation of complex tumor biology, including hypoxic/necrotic cores and dense vascular networks, a crucial advancement over prior models. The platform features a user-friendly, gravity-driven flow system. Using HepG2 and Hep3b liver cancer cells, it generated optimized tumor spheroids (>500 μm) within a complex tumor microenvironment (TME) with self-assembled, perfusable vascular networks exhibiting *in vivo*-like permeability ($\sim 1.8 \times 10^{-7}$ cm/s), making it suitable for drug delivery investigations. The model successfully mimicked key determinants of therapeutic efficacy: a hypoxic core, extracellular matrix, and functional vasculature. Vascularization promoted tumor proliferation and reduced hypoxia. Differential responses to sorafenib (a tyrosine kinase inhibitor used in patients with hepatocellular carcinoma (HCC)), across tumor subtypes mirrored clinical

heterogeneity of treatment outcomes, highlighting complex resistance mechanisms, attributable to tumor-ECM interactions. Furthermore, the model elucidated the paradoxical role of tumor vasculature in CD133⁺ chimeric antigen receptor T-cell (CAR-T) cell therapy against HCC: tumor endothelium acted as a physical barrier to T-cells' infiltration, yet the few successfully infiltrated cells retained potent cytotoxic function and exhibited reduced exhaustion markers within the TME. Spatial profiling of the tumor microenvironment uncovered specific activation and exhaustion signatures in the engineered T-cells, OrganiX™, thus, has been projected as a powerful, controlled *in vitro* tool to dissect TME mechanisms influencing therapy, complementing *in vivo* studies and accelerating personalized therapeutic development.

Key Challenges, Prospective Solutions and Future Research Avenues

As evident, microfluidics-assisted vOoC platforms hold immense potential for revolutionizing biomedical research. However, the successful realization of this prospect necessitates overcoming a multitude of intricate engineering, biological, and translational challenges.

A primary set of hurdles revolves around *device fabrication and engineering*. Achieving precise micro-channel dimensions for consistent fluid flow and proper cell behavior remains complex, particularly when integrating multiple components like sensors, valves, and pumps. Air bubble formation within microdevices consistently disrupts function and harms cells, demanding robust priming methods and automated detection/removal systems [18]. The development process itself is time-consuming, often spanning days for PDMS devices to weeks for gel-based systems [18]. Moreover, ensuring reproducibility across devices is critical yet challenging due to inherent sensitivity to environmental fluctuations and equipment malfunctions. Material limitations, including drug absorption by common polymers like PDMS, biocompatibility issues, and biofouling, also demand novel solutions. Maintaining precise flow control for nutrient/oxygen transport and shear stress is crucial but can be difficult to achieve dynamically [24], as is the uniform distribution of high densities of ECs in small-diameter microchannels [18]. High scattering of turbid tissues in vOoC models limits optical imaging depth [19]. Moreover, scaling up production for high-throughput applications and integrating these systems into multi-organ platforms introduces significant cost and time constraints.

Beyond engineering, *biological mimicry* presents profound challenges. Replicating the intricate branching and hierarchical structure of *in vivo* vascular networks, complete with dynamic physiological conditions like pulsatile flow and the precise incorporation of diverse cell types, is a complex task. A major drawback

is the significant underrepresentation of the immune system in most OoCs, lacking key immune organs and diverse immune cell populations, which severely limits accurate modeling of systemic infections, inflammation, and hemostatic issues [11]. Furthermore, the typically short lifespan (14-21 days) of OoC cultures restricts the study of chronic diseases and long-term vascular remodeling, as cells in artificial environments can eventually regress or undergo apoptosis. Ensuring physiologically relevant barrier function and using appropriate organ-specific ECs are also critical for high-fidelity modeling.

Addressing these complex challenges requires *multifaceted prospective solutions and future research themes*. Advancements in fabrication involve standardized modular platforms, advanced 3D bioprinting, and AI-guided design optimization, alongside rapid prototyping techniques. Automated bubble management and robust fluidic systems with real-time feedback control are essential for reproducibility. Research into novel biomaterials, dynamic surface functionalization, and integrated biosensors is crucial for improved biocompatibility and real-time monitoring of physiological parameters. To enhance biological fidelity, strategies include incorporating organoid-derived immune compartments, expanding co-cultures with diverse immune cell populations, harnessing stem cell-biology for extended viability, and developing improved ECM mimics and dynamic culture systems. Overcoming the limitations in vascular complexity replication necessitates advanced biomanufacturing techniques (*e.g.*, two-photon polymerization) and specialized cell seeding methods. For example, Grebenyuk et al. (2023)'s 3D soft microfluidic strategy relied on a 3D-printable, 2-photon-polymerizable hydrogel to precisely print microvessels below living tissues' diffusion limit [36]. This enabled the creation of large, viable, and proliferative engineered tissues with complex morphogenesis over long-term culture, preventing hypoxia and necrosis. By the same token, employing tissue optical clearing (TOC) with efficient large-scale efficient data analysis methods can assist in comprehensive 3D visualization of vOoCs [19].

Ultimately, standardizing validation methods, miniaturizing analytical platforms, and creating unified data-protocols are vital for translational utility. The collective efforts, bridging bioengineering, material science, immunology, and computational modeling, are poised to transform these promising platforms from laboratory innovations into clinically and industrially relevant tools for drug discovery, disease modeling, and personalized medicine. Before I wind up, I wish to draw the readers' attention to Gaillard et al. (2023)'s typology of organoid technology from a philosophical and ethical perspective. Its core argument is that different types of organoids possess distinct emerging properties, leading to varied ethical implications [37]. By classifying these biotechnological

constructs, the authors have attempted to clarify the complex ethical landscape surrounding organoid research, addressing both traditional ethical concerns (like informed consent) that are amplified by organoids' novel nature, and new challenges arising from properties such as potential sentience (neural organoids) or organismal capabilities (embryo models).

Conclusions

A brief overview on the strategies to harness microfluidics for vascularization of OoC platforms, the advantages and key challenges of this technology, as well as few topical reports across various biomedical/bioengineering applications were presented in this article. OoC models offer significant advantages in drug discovery and personalized medicine by reducing animal reliance and improving clinical outcome predictions. Vascularization is crucial for accurately mimicking the complex tissue microenvironment within these models, enabling researchers to study disease progression and evaluate therapeutic interventions effectively. Microfluidics plays a pivotal role in achieving vascularization within OoC models. By precisely controlling fluid flow, these devices recreate physiological conditions such as shear stress and pulsatile flow, critical for EC function and vascular network formation. Furthermore, microfluidic platforms allow for the creation of gradients of growth factors, mimicking their spatial distribution *in vivo* and enabling the study of angiogenesis. Current vascular chips primarily focus on specific organs, while the development of universal platforms is a critical next step. Challenges are encountered in integrating complex vascular networks, encompassing fabrication complexities, ensuring long-term patency and stability, and faithfully replicating tissue-specific microenvironments. Advancements in vascularization technology are envisaged to drive the development of interconnected OoC systems. This requires interdisciplinary collaboration among experts in biomaterials, microfluidics, and cell biology. Universal chips will significantly impact personalized medicine, particularly in drug screening for individual tumors, and streamline clinical trials. Such progress can pave the way towards the creation of human-on-a-chip models, which hold immense potential for revolutionizing organ transplantation.

Abbreviations

AI: Artificial Intelligence;
BBB: Blood Brain Barrier;
CAFs: Cancer-Associated Fibroblasts;
CAM: Chorioallantoic Membrane;
CAR-T: Chimeric Antigen Receptor T-cell;
CMS: Cardiomyocytes;
CNS: Central Nervous System; **CO:** Cerebral Organoid;
COC: Cyclic Olefin Copolymer;
CTNNB1: Catenin beta-1;

CYR61: Cysteine-Rich Angiogenic Inducer 61; **EC:** Endothelial Cells;
ECM: Extracellular Matrix;
EGFP: Enhanced Green Fluorescent Protein;
HCC: Hepatocellular Carcinoma;
HDGF: Hepatoma-Derived Growth Factor;
hESC: Human Embryonic Stem Cell;
hiPSC: Human Induced Pluripotent Stem Cell;
hLFs: Human Lung Fibroblasts;
HUVECs: Human Umbilical Vein ECs;
IF: Interstitial Flow;
LSECs: Liver Sinusoidal Endothelial Cells;
MEKs: Mouse Embryonic Kidneys;
MMP-2: Matrix Metalloproteinase-2;
MVN: Microvascular Networks;
OoC: Organoid-on-a-Chip;
PDAC: Pancreatic Ductal Adenocarcinoma;
PDMS: Polydimethylsiloxane;
SH: Sclerotomy + HUVECs;
SOX-9: SRY-Box Transcription Factor 9;
TME: Tumor Microenvironment;
TOC: Tissue Optical Clearing;
ToC: Tumor-on-a-Chip;
VB: Vascular Bed;
VCAM-1: Vascular Cell Adhesion Molecule 1;
VEGFA: Vascular Endothelial Growth Factor A;
VoC: Vessel-on-a-Chip/Vasculature-on-a-Chip;
VOD: Veno-Occlusive Disease;
vOoC: Vascularized Organoid-on-a-Chip;
VPTKIs: VEGFR2/PDGFR-Inhibiting Tyrosine Kinase Inhibitors;
vToC: Vascularized Tumor-on-a-Chip.

Author Contributions

I was involved in literature review and analysis, writing, reviewing and editing the manuscript.

Availability of Data and Materials

Not applicable

Consent for Publication

The various panels in Figure 1 have been reproduced under the provisions of Creative Commons Attribution License 4.0.

Conflict of Interest

None.

Funding

No external funding was received for compilation of this article.

References

- [1] Raheem, A.; Mandal, K.; Biswas, S.; Ahari, A.; Hassani Najafabadi, A.; Farhadi, N., ... & Manivasagam, G. Smart biomaterials in healthcare: Breakthroughs in tissue engineering, immunomodulation, patient-specific therapies, and biosensor applications. *Applied Physics Reviews* **2025** *12*(1) 011333. <https://doi.org/10.1063/5.0238817>
- [2] Konwarh, R. Can the venerated silk be the next-generation nanobiomaterial for biomedical-device designing, regenerative

- medicine and drug delivery? Prospects and hitches. *Bio-Design and Manufacturing* **2019**, *2* (4), 278–286. <https://doi.org/10.1007/s42242-019-00052-9>.
- [3] Kaushik, A.; & Garg, R. K. Tapping the potential of rapid prototyping techniques in creating a paradigm shift in the fabrication of occlusal splints. *Rapid Prototyping Journal* **2023** *29*(10), 2176–2192. <https://doi.org/10.1108/RPJ-12-2022-0412>
- [4] Reardon, P. J., Konwarh, R., Knowles, J. C., & Mandal, B. B. (2017). Mimicking hierarchical complexity of the osteochondral interface using electrospun silk-bioactive glass composites. *ACS Applied Materials & Interfaces*, *9*(9), 8000–8013. <https://doi.org/10.1021/acsami.6b16590>
- [5] Konwarh, R.; Gupta, P.; Mandal, B. B. Silk-microfluidics for advanced biotechnological applications: A progressive review. *Biotechnology Advances* **2016**, *34* (5), 845–858. <https://doi.org/10.1016/j.biotechadv.2016.05.001>.
- [6] Zhao, Y.; Wang, E. Y.; Lai, F. B. L.; Cheung, K.; Radisic, M. Organs-on-a-chip: a union of tissue engineering and micro-fabrication. *Trends in Biotechnology* **2023**, *41* (3), 410–424. <https://doi.org/10.1016/j.tibtech.2022.12.018>.
- [7] Huang, Y.; Liu, T.; Huang, Q.; Wang, Y. From Organ-on-a-Chip to Human-on-a-Chip: A Review of Research Progress and Latest Applications. *ACS Sensors* **2024**, *9* (7), 3466–3488. <https://doi.org/10.1021/acssensors.4c00004>.
- [8] Versteegen, M. M.; Coppes, R. P.; Beghin, A.; De Coppi, P.; Gerli, M. F.; de Graeff, N.; ... & van der Laan, L. J. Clinical applications of human organoids. *Nature Medicine* **2025**, *31*, 409–421. <https://doi.org/10.1038/s41591-024-03489-3>
- [9] Lim, J.; Fang, H.-W.; Bupphathong, S.; Sung, P.-C.; Yeh, C.-E.; Huang, W.; Lin, C.-H. The Edifice of Vasculature-On-Chips: A Focused Review on the Key Elements and Assembly of Angiogenesis Models. *ACS Biomaterials Science & Engineering* **2024**, *10* (6), 3548–3567. <https://doi.org/10.1021/acsbomaterials.3c01978>.
- [10] Moreira, H. R.; Marques, A. P. Vascularization in skin wound healing: where do we stand and where do we go? *Current Opinion in Biotechnology* **2022**, *73*(1), 253–262. <https://doi.org/10.1016/j.copbio.2021.09.020>
- [11] Wakabayashi, T.; Naito, H. Cellular heterogeneity and stem cells of vascular endothelial cells in blood vessel formation and homeostasis: Insights from single-cell RNA sequencing. *Frontiers in Cell and Developmental Biology* **2023**, *11*. <https://doi.org/10.3389/fcell.2023.1146399>
- [12] Cuenca, M. V.; Bulut, M.; Mummery, C. L.; & Orlova, V. Vascularization of Organoid Microenvironments: Perfusable Networks for Organoid Growth and Maturation. *Current Opinion in Biomedical Engineering* **2025**, *34*, 100586.
- [13] Varma, A. R.; Fathi, P. Vascularized microfluidic models of major organ structures and cancerous tissues. *Biomicrofluidics* **2023**, *17* (6). <https://doi.org/10.1063/5.0159800>
- [14] Quintard, C.; Tubbs, E.; Jonsson, G.; Jiao, J.; Wang, J.; Werschler, N.; Laporte, C.; Pitaval, A.; Bah, T.-S.; Pomeranz, G.; Bissardon, C.; Kaal, J.; Leopoldi, A.; Long, D. A.; Blandin, P.; Achard, J.-L.; Battail, C.; Hagelkruys, A.; Navarro, F.; Fouillet, Y.; Penninger, J. M.; Gidrol, X. A microfluidic platform integrating functional vascularized organoids-on-chip. *Nature Communications* **2024**, *15* (1). <https://doi.org/10.1038/s41467-024-45710-4>
- [15] Papamichail, L.; Koch, L. S.; Veerman, D.; Broersen, K.; & van der Meer, A. D. Organoids-on-a-chip: microfluidic technology enables culture of organoids with enhanced tissue func-

- tion and potential for disease modeling. *Frontiers in Bioengineering and Biotechnology* **2025**, *13*, 1515340.
- [16] Moses, S. R.; Adorno, J. J.; Palmer, A. F.; Song, J. W. Vessel-on-a-chip models for studying microvascular physiology, transport, and function in vitro. *AJP Cell Physiology* **2020**, *320*(1), C92-C105. <https://doi.org/10.1152/ajpcell.00355.2020>.
- [17] Chauhdari, T.; Zaidi, S. A.; Su, J.; & Ding, Y. Organoids meet microfluidics: recent advancements, challenges, and future of organoids-on-chip. *In vitro models* **2025**, *4*, 71-88. <https://doi.org/10.1007/s44164-025-00086-7>.
- [18] Iqbal, M. Z.; Riaz, M.; Biedermann, T.; Klar, A. S. Breathing new life into tissue engineering: exploring cutting-edge vascularization strategies for skin substitutes. *Angiogenesis* **2024**. <https://doi.org/10.1007/s10456-024-09928-6>.
- [19] Yu, T.; Yang, Q.; Peng, B.; Gu, Z.; & Zhu, D. Vascularized organoid-on-a-chip: design, imaging, and analysis. *Angiogenesis* **2024**, *27*(2), 147-172.
- [20] Wang, W.; Su, W.; Han, J.; Song, W.; Li, X.; Xu, C.;... & Wang, L. Microfluidic platforms for monitoring cardiomyocyte electromechanical activity. *Microsystems & Nanoengineering* **2025**, *11*(1), 4. <https://doi.org/10.1038/s41378-024-00751-z>.
- [21] Wang, L.; Han, J.; Su, W.; Li, A.; Zhang, W.; Li, H.; ... & Chen, J. Gut-on-a-chip for exploring the transport mechanism of Hg (II). *Microsystems & Nanoengineering* **2023**, *9*(1), 2. <https://doi.org/10.1038/s41378-022-00447-2>.
- [22] Gonzalez-Rubio, J.; Kubiza, H.; Xu, Y.; Koenigs-Werner, H.; Schmitz, M. S.; Schedel, M.; ... & Thiebes, A. L. Pericytes promote more vascularization than stromal cells via an interleukin-6-dependent mechanism in microfluidic chips. *Advanced Science* **2025**, *12*(14), 2408131. <https://doi.org/10.1002/advs.202408131>.
- [23] Zhang, S.; Wan, Z.; Pavlou, G.; Zhong, A. X.; Xu, L.; & Kamm, R. D. Interstitial flow promotes the formation of functional microvascular networks in vitro through upregulation of matrix metalloproteinase-2. *Advanced Functional Materials* **2022**, *32*(43), 2206767. <https://doi.org/10.1002/adfm.202206767>.
- [24] Shakeri, A.; Wang, Y.; Zhao, Y.; Landau, S.; Perera, K.; Lee, J.; Radisic, M. Engineering Organ-on-a-Chip Systems for Vascular Diseases. *Arteriosclerosis Thrombosis and Vascular Biology* **2023**, *43* (12), 2241-2255. <https://doi.org/10.1161/atvbaha.123.318233>.
- [25] Lansche, C.; Ladaigue, S.; Gropplero, G.; Zimmermann, N.; Nurmik, M.; Veith, I.;... & Parrini, M. C. Bioengineering a Patient-Derived Vascularized Lung Tumor-on-Chip Model to Decipher Immunomodulation by the Endothelium. *Advanced Healthcare Materials* **2025**, 2403446. DOI: 10.1002/adhm.202403446.
- [26] Nguyen, D.-H. T.; Lee, E.; Alimperti, S.; Norgard, R. J.; Wong, A.; Lee, J. J.-K.; Eyckmans, J.; Stanger, B. Z.; Chen, C. S. A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling. *Science Advances* **2019**, *5* (8). <https://doi.org/10.1126/sciadv.aav6789>.
- [27] Jusoh, N.; Ko, J.; Jeon, N. L. Microfluidics-based skin irritation test using in vitro 3D angiogenesis platform. *APL Bioengineering* **2019**, *3* (3). <https://doi.org/10.1063/1.5093975>.
- [28] Mozneb, M.; Jenkins, A.; Sances, S.; Pohlman, S.; Workman, M. J.; West, D.; Ondatje, B.; El-Ghazawi, K.; Woodbury, A.; Garcia, V. J.; Patel, S.; Arzt, M.; Dezem, F.; Laperle, A. H.; Moser, V. A.; Ho, R.; Yucer, N.; Plummer, J.; Barrett, R. J.; Svendsen, C. N.; Sharma, A. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells. *Lab on a Chip* **2024**, *24* (4), 869-881. <https://doi.org/10.1039/d3lc00745f>.
- [29] Arslan, U.; Van Den Hil, F. E.; Mummery, C. L.; Orlova, V. Generation and Characterization of hiPSC-Derived Vascularized-, Perfusable Cardiac Microtissues-on-Chip. *Current Protocols* **2024**, *4* (7). <https://doi.org/10.1002/cpz1.1097>.
- [30] Kesharwani, A.; Tani, S.; Nishikawa, M.; Sakai, Y.; Okada, H.; Ohba, S.; ... & Hojo, H. Modeling vascular dynamics at the initial stage of endochondral ossification on a microfluidic chip using a human embryonic-stem-cell-derived organoid. *Regenerative Therapy* **2025**, *28*, 90-100. <https://doi.org/10.1016/j.reth.2024.11.018>.
- [31] Oliveira, M.; Sarker, P. P.; Skovorodkin, I.; Kalantarifard, A.; Haskavuk, T.; Mac Intyre, J.; ... & Raykhel, I. From *ex ovo* to *in vitro*: xenotransplantation and vascularization of mouse embryonic kidneys in a microfluidic chip. *Lab on a Chip* **2024**, *24*(20), 4816-4826. <https://doi.org/10.1039/D4LC00547C>.
- [32] Shaji, M.; Tamada, A.; Fujimoto, K.; Muguruma, K.; Karsten, S. L.; & Yokokawa, R. Deciphering potential vascularization factors of on-chip co-cultured hiPSC-derived cerebral organoids. *Lab on a Chip* **2024**, *24*(4), 680-696. <https://doi.org/10.1039/D3LC00930K>.
- [33] Casademont-Roca, A.; Xing, Z.; Bernardi, M.; Rookmaker, M.; de Kort, L.; & de Graaf, P. A novel vascularized urethra-on-a-chip model. *Scientific Reports* **2025**, *15*(1), 8062. <https://doi.org/10.1038/s41598-025-92485-9>.
- [34] Bonanini, F.; Kurek, D.; Previdi, S. *et al.* In vitro grafting of hepatic spheroids and organoids on a microfluidic vascular bed. *Angiogenesis* **2022**, *25*, 455-470. <https://doi.org/10.1007/s10456-022-09842-9>.
- [35] Vasudevan, J.; Vijayakumar, R.; Reales-Calderon, J. A.; Lam, M. S.; Ow, J. R.; Aw, J.; ... & Pavesi, A. *In vitro* integration of a functional vasculature to model endothelial regulation of chemotherapy and T-cell immunotherapy in liver cancer. *Biomaterials* **2025**, *320*, 123175. <https://doi.org/10.1016/j.biomaterials.2025.123175>.
- [36] Grebenyuk, S.; Abdel Fattah, A. R.; Kumar, M.; To-prakhisar, B.; Rustandi, G.; Vananroye, A.; ... & Ranga, A. Large-scale perfused tissues via synthetic 3D soft microfluidics. *Nature Communications* **2023**, *14*(1), 193. <https://doi.org/10.1038/s41467-022-35619-1>.
- [37] Gaillard, M.; Pence, C. H.; & Botbol-Baum, M. Organoid Ethical Typology: varieties of three-dimensional stem cell constructs and the many issues they raise in bioethics. *Biology of the Cell* **2025** *117*(1), e2400093. <https://doi.org/10.1111/boc.202400093>.